



Contribution of the Leukocyte Adherence Inhibition Test to the Diagnosis of Innate Non-IgE-mediated Immunoreactivity against *Alternaria alternata*

Celso Eduardo Olivier ^{a*}, Daiana Guedes Pinto ^a,
Ana Paula Monezzi Teixeira ^a,
Jh essica Let icia Santos Santana ^a,
Raquel Ac acia Pereira Gonalves Santos ^a,
Regiane Patussi Santos Lima ^b
and Everton Salgado Monteiro ^c

^a Instituto Alergoimuno de Americana, Brazil.

^b Lavoisier's Laboratories, S ao Paulo, Brazil.

^c Department of Allergy and Immunopathology, Faculty of Medicine, S ao Paulo University, Brazil.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/107037>

Original Research Article

Received: 02/09/2023

Accepted: 28/09/2023

Published: 03/10/2023

*Corresponding author: E-mail: celso@alergoimuno.med.br;

ABSTRACT

Aims: To evaluate the potential of the Leukocyte Adherence Inhibition Test (LAIT) to discriminate innate immunoreactivity against *Alternaria alternata* in patients with clinical suspicion of allergic reaction to fungal allergens.

Study Design: We retrospectively examined the medical charts of 100 patients diagnosed with Allergic Rhinitis and/or Asthma with clinical suspicion of fungal hypersensitivity who were investigated with an *ex vivo* challenge monitored by LAIT against the extract of *A. alternata*.

Place and Duration of Study: Instituto Alergoimuno de Americana – São Paulo – Brazil – between January 2018 and August 2023.

Methodology The percentage of Leukocyte Adherence Inhibition (LAI) promoted by the *ex vivo* challenges with *A. alternata* extract was distributed in ranges through a cascade distribution chart to outline the variability of the results.

Results: The mean LAI was 50%; SD 22,2%, ranging from 0% to 94%; mode = 58% (appeared five times). There was a wide range of distribution of LAI results, suggesting that some patients had immunoreactivity against the *A. alternata* allergens while others did not.

Conclusion: Our preliminary results support that the LAIT performed with *A. alternata* may differentiate diverse degrees of *ex vivo* immunoreactivity against this airborne antigen in allergic patients.

Keywords: Allergy; *Alternaria alternata*; asthma; diagnosis; hypersensitivity; leukocyte adherence inhibition test; Non-IgE-mediated immunoreactivity; rhinitis.

1. INTRODUCTION

Alternaria alternata (first known as *Alternaria tenuis*) is a cosmopolitan, imperfect fungus reproducing through allergenic airborne spores responsible for several human diseases [1]. *A. alternata* is an anemophilous, melanin-pigmented fungus that forms fast-growing colonies in dark colors ranging from gray to olive brown [2]. *A. alternata* may exist in the soil, the atmosphere, plants, and indoor environments such as carpets, tatami mats, pillows, sofas, walls, air conditioners, dishwashers, and washing machines [3-5]. Exposure to *A. alternata* can cause allergic rhinitis, asthma, and atopic dermatitis [6,7]. Also known as "Blackmould," *A. alternata* is also a crop pest of tomato horticulture [8]. *Alternaria* species can also contaminate silage corn and hay, turning them into believable allergens to be liable for the historical description of "hay fever" [9]. At convenient temperatures and humidity, *A. alternata* produces mycotoxins, such as alternariol, that may impregnate food [10]. Opportunistic infestations such as chronic sinusitis and cutaneous alternariosis are described in immunodeficient patients [11,12]. *A. alternata* is the most representative fungal aeroallergen, a target of outstanding efforts to develop new and improved desensitization techniques, such as polymerized allergoids [13]. In allergic humans, exposure to allergenic molds

can cause allergic rhinitis, asthma, and atopic dermatitis [14].

The role of the Interleukins (IL) IL-4, IL-5, IL-9, and IL-13, along with STAT6 signaling, is a well-known mechanistic pathway leading to IgE-mediated allergic diseases [15,16]. Besides the mainstream IgE-mediated hypersensitivity, *A. alternata* antigens can interact with innate immune cells, especially with Innate Lymphoid Cells (ILCs), increasing the inflammatory response induced by other allergens [17]. ILCs do not express lineage markers (lineage-negative); however, they can secrete cytokines that respond to pathogenic stimuli, shaping subsequent innate and adaptive immunity [18]. *A. alternata* induces the activation of the type 2 subset of Innate Lymphoid Cells (ILC2s) that have the innate ability to express high levels of T helper type 2 (Th2) cytokines [19]. Asthmatic patients typically present enhanced innate type 2 immune response, with almost twice ILC2s circulating in the peripheral blood compared to health controls [20]. This innate response is STAT6-dependent and leads to airway eosinophilia, peribronchial fibrosis, and thickness of the airway epithelium [21]. RAG1-deficient mice do not produce mature B and T cells [22]; however, they can generate ILC2-dependent allergen-induced memory when exposed to *A. alternata* allergens [23]. The activation of ILC2s is faster than the typical allergic response

mediated by T cells and B cells, depends on the microenvironment and cell-to-cell signals, and is independent of specific antigen stimulation [24]. Respiratory *in vivo* challenges with *A. alternata* allergens elicit a rapid increase and activation of IL-33-responsive ILC2s (Lin⁻CD25⁺CD44^{hi}) prepped to secrete IL-5 and IL-13, driving eosinophilic inflammation without B or T cells [25]. The IL-33 and its receptor (i.e., ST2) are a shared gateway for this innate pathway and its adaptive counterpart driven by allergen-reactive Th2 cells (CD4⁺ Th2-type T cells), which orchestrate immune responses by the production of immunoglobulins [26]. Besides amplifying innate and Th2-type responses, IL-33 also amplifies Th1-response, enhancing the liberation of IFN- γ [27]. Full-length IL-33 is an alarmin cytokine that works as an environmental sensor, detecting proteolytic activity inside a large spectrum of allergens encompassing bacteria, fungi, mites, and pollens [28,29]. Alarmins, such as IL-33, IL-25, and thymic stromal lymphopoietin (TSLP), are ILC2-activating signals driving ILC2 growth and proinflammatory cytokine production [30].

Despite the immune blockage of IL-33 becoming a realistic target for treating refractory allergic inflammation, there is still a lack of laboratory exams to evaluate this type of immune cellular circuit activation at the clinical set [31]. When investigating an allergic patient with a clinical suspicion of hypersensitivity against *A. alternata*, the primary information that a complementary lab exam can provide is about the presence or the undetectability of specific IgE [32]. The research laboratory procedures used to elucidate innate hypersensitivity are too expensive and complex to be available to the contemporary clinical set. In search of a viable alternative, we employ the Leukocyte Adherence Inhibition Test (LAIT), performed artisanally at our modest laboratory installations annexed to our outpatient clinic. The LAIT is a simple and quick *ex vivo* laboratory procedure, made with viable leukocytes, able to demonstrate immunoreactivity against fungal allergens such as *Candida albicans* and airborne fungal allergens [33-35].

To evaluate the potential of the Test (LAIT) Leukocyte Adherence Inhibition to reproduce non-IgE-mediated innate immunoreactivity against the *A. alternata*, we retrospectively examined the medical charts of patients investigated with an *ex vivo* challenge monitored by LAIT against an *A. alternata* extract. These

patients, diagnosed with allergic rhinitis or asthma, had clinical suspicion of allergic reactions to fungal allergens, had non-reactive skin tests, and undetectable specific IgE for *A. alternata*.

2. MATERIALS AND METHODS

2.1 Subjects

After receiving Institutional Review Board approval from the Instituto Alergoimuno de Americana (Brazil; 06/2023), we proceeded with the electronic chart review of 7,700 allergic patients who attended our outpatient facility from January 2018 to August 2023. A cohort of 100 patients had been submitted to an *ex vivo* allergen challenge test with *A. alternata* extract monitored with LAIT. The cohort counted 37 males; mean age 37 years; SD 24.4 years; range 1 to 88 years; modes = 31 (appeared eight times); geometric mean = 25,5 years. We offer this procedure to patients with allergic rhinitis or asthma associated with the inhalation of fungal allergens who had an inconclusive investigation performed with allergic skin tests and undetectable specific IgE against *A. alternata* performed with ImmunoCAP® [36].

2.2 Antigen Preparation

The strains of *A. alternata* were cultivated in Czapek medium during three weeks of incubation at 28°C. The fungal culture was filtered through a 0.45 μ m filter to obtain the fungal mass from which the micellar molecules were extracted. Extraction was performed at 4°C for 24 hours, using a 0.125M ammonium bicarbonate extraction buffer, pH 7.5, with a high-speed stirrer. After 24 hours of extraction, the content was filtered through a coarse and 0.45 μ m filter. The protein concentration was estimated spectrophotometrically (1.36 mg/mL) and diluted to 1 mg/mL in antigen dilution solution (NaCl 10 g, KH₂PO₄ 0.72 g, Na₃PO₄ 2.86 g, methylparaben 1 g, propylparaben 0.5 g, glycerin 400 mL, H₂O 600 mL) and used to perform the LAIT and allergic skin tests [37].

2.3 *Ex vivo* Investigation: Leukocyte Adherence Inhibition Test

We performed the LAIT as previously described [38-46]. Shortly, each donor's fresh plasma was divided into two parts and used in paralleled *ex vivo* challenging tests with *A. alternata* extract

and the unchallenged plasma assay. We collected the plasma with high leukocyte content (buffy coat) from the heparinized tube after one hour of sedimentation at 37°C. Then we distributed aliquots of 100 µL into Eppendorf tubes kept under agitation for 30 minutes (200 rpm at 37°C) with (or without, as used as control) antigen extract (10µL of a solution with 1mg/mL and pH 7.5). After incubation, the plasma was allocated into a standard Neubauer hemocytometer counting chamber with a plain, non-metallic glass surface and left to stand for 2 hours at 37°C in the humidified atmosphere of the covered water bath to allow leukocytes to adhere to the glass. Next, we counted the leukocytes, removed the coverslip, and washed the chamber by immersion in a beaker with PBS at 37°C. Then, we added a drop of PBS to the hemocytometer's chamber and allocated a clean coverslip over it. The remaining cells were counted in the same squares as previously examined. The percentage of Leukocyte Adherence (LA) of each assay was estimated as: (the number of leukocytes observed on the hemocytometry chamber after washing divided by the number of leukocytes observed on the hemocytometry chamber before washing) and multiplied by 100 (%). The Leukocyte Adherence Ratio (LAR) was estimated based on the ratio between the LA from the antigen-specific

challenged groups and the LA from the unchallenged control group: $LAR = \frac{LA \text{ of the challenged sample}}{LA \text{ of unchallenged control sample}} \times 100$ (%). To further calculate the Leukocyte Adherence Inhibition (LAI), we subtracted the LAR from 100 (%). We employed the LAI results for the statistics calculations and the cascade distribution chart.

3. RESULTS

As a retrospective survey, there was no research protocol; therefore, we report the incidental immune investigation as registered in the digital medical charts. The mean LAI was 50%; SD 22,2%, ranging from 0% to 94%; mode = 58% (appeared five times). There was a wide range of distribution of LAI results, as outlined by the cascade distribution chart in Fig. 1. Three patients (3% of the tests) ignored the presence of the allergen on the plasma and presented no inhibition of leukocyte adherence after contact with the *A. alternata* extract. Some patients showed strong immunoreactivity during the *ex vivo* challenge test against the *A. alternata* extract, which possibly would reflect the allergic symptoms after exposure to the allergen. In contrast, other patients displayed low or moderate immunoreactivity.




Fig. 1. Cascade distribution chart of the range groups of Leukocyte Adherence Inhibition (LAI) results (x-axis %) of *ex vivo* *A. alternata* extract challenges monitored by the Leukocyte Adherence Inhibition Test (LAIT), according to the respective percentage of outcomes over 100 tests (y-axis)

4. DISCUSSION

The substantial improvement in knowledge about cytokine interactions from the beginning of the 21st century made us increasingly realize that IgE-mediated allergic reactions are only a tiny fraction of the complex world of hypersensitivity [47]. The discovery of Innate Lymphoid Cells prepared to carry out functions formerly attributed only to the Adaptive Immune System was a paradigm shift already anticipated by several researchers [48]. The first clues about an innate cell able to generate Type 2 immune reactions derived from animal studies about immunity against helminths [49]. Tissue-resident type 2 Innate Lymphoid Cells (ILC2s) are highly responsive effectors in type 2 inflammation [50]. Soon, researchers realized the involvement of ILC2s with human allergic diseases. The ILC2s do not directly recognize specific allergens, but when stimulated by alarmins or cytokines released by damaged epithelium or neighbor immune cells, they generate Th2-type cytokines [51]. Type 2 ILCs release cytokines such as IL-4, IL-5, IL-9, and IL-13 independently of the participation of the classic Th2 cells first reported within the context of the adaptive immune system [52]. As a fungus, besides the specific IgE allergens, such as the dimeric β -barrel protein Alt a 1, *A. alternata* also possesses beta-glucans, a Pathogen-Associated Molecular Pattern (PAMP), recognized by innate receptors known as Pattern Recognition Receptors (PRRs) such as the Dectin-1, a primary β -glucan receptor, [53-56]. This innate recognition turns *A. alternata* into a perfect candidate for developing non-IgE-mediated innate Th2-like allergic reactions [57]. Besides innate cellular activation, *Alternaria*-derived serine protease drives IL-33-mediated allergic inflammation [58]. The IgE-mediated hypersensitivity against *A. alternata* is easily investigated by cutaneous skin tests or by automatized ImmunoCAP® [59]. However, physicians do not readily recognize non-IgE-mediated or innate *A. alternata* hypersensitivity unless they have access to sophisticated laboratory techniques such as the Basophil Activation Test, the Lymphocyte Stimulation Test, the Leukocyte Migration Inhibition Test, or the LAIT [60-65].

The *ex vivo* challenge test performed with the leukocyte buffy coat allows the interaction of all types of peripheral blood immune cells with the allergen, theoretically exploiting an extensive range of different immune possibilities. This technique includes the participation of reactions

orchestrated by alarmin cytokines, innate ILCs, and adaptive (IgE and Non-IgE) antibody-mediated reactions, classified as Types I, II, and III by Gell & Coombs, and possibly the cellular Type IV [66,67]. The LAIT is not specific for any pathway since it observes a final resultant phenomenon: the leukocytes' glass-adherence inhibition after contact with tested antigens [68-71].

This preliminary retrospective survey has demonstrated in a group of allergic patients a great range of results against the *ex vivo* challenge against *A. alternata* extract, suggesting that some patients already had a previous immunological experience with their antigens, while others did not. We employed LAIT as a complementary triage test to select worthwhile antigens to proceed with the more exhaustive *in vivo* provocations, mainly when the specific IgE is undetectable. More studies with prospective larger double-blind cohorts need to evaluate the potential contribution of LAIT in managing patients with *A. alternata* non-IgE-mediated innate hypersensitivity.

5. CONCLUSION

Our preliminary results support that the LAIT may differentiate diverse degrees of *ex vivo* non-IgE-mediated innate immunoreactivity against the *A. alternata* extract, indicating a previous immune experience with this agent. The limitation of the present study is that it is an analysis of a retrospective cohort, presenting only an overview of the immunoreactivity of patients with similar medical conditions. The LAIT positivity does not necessarily prove that the symptoms that motivate the patient to seek medical help happened due to this specific tested antigen. The clinical diagnosis, instead, is better accomplished by the responses to the *in vivo* challenges, the real-world presence of the agent in the environment inhabited by the patient, the exclusion of the allergen's source from the patient's life, and the close observance of the symptoms after its re-introduction. As future directions, we devise to associate the LAIT with more sophisticated techniques, such as the quantification of Interleukins (for instance, the IL-33), and to associate it with *in vivo* challenge tests.

CONSENT

As a retrospective survey of results recorded *incognito*, consent was given collectively by the

institution's ethics committee following the principles of the Declaration of Helsinki [72].

ETHICAL APPROVALS

The authors have collected and preserved written ethical approval per international standards.

ACKNOWLEDGEMENTS

The Instituto Alergoimuno de Americana funded this work.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- Kustrzeba-Wójcicka I, Siwak E, Terlecki G, Wolańczyk-Mędrala A, Mędrala W. *Alternaria alternata* and Its Allergens: A Comprehensive Review. *Clin Rev Allergy Immunol*. 2014;47(3):354-365.
- Kawamura C, Moriwaki J, Kimura N, Fujita Y, Fuji S, Hirano T, et al. The melanin biosynthesis genes of *Alternaria alternata* can restore pathogenicity of the melanin-deficient mutants of *Magnaporthe grisea*. *Molecular Plant-Microbe Interactions: MPMI*. 1997;10(4):446-53.
- Sánchez P, Vélez-Del-Burgo A, Suñén E, Martínez J, Postigo I. Fungal Allergen and Mold Allergy Diagnosis: Role and Relevance of *Alternaria alternata* Alt a 1 Protein Family. *J of Fungi (Basel, Switzerland)* 2022;8(3):277.
- Hamada N, Fujita T. Effect of air-conditioner on fungal contamination. *Atmosf Environ*. 2002;36(35):5443-5448.
- Nambu M, Kouno H, Aihara-Tanaka M, Shirai H, Takatori K. Detection of Fungi in Indoor Environments and Fungus-Specific IgE Sensitization in Allergic Children. *World Allergy Org J*. 2009;2(9):208-212.
- López-Couso VP, Tortajada-Girbés M, Rodríguez-Gil D, Martínez-Quesada J, Palacios-Pelaez R. Fungi Sensitization in Spain: Importance of the *Alternaria alternata* Species and Its Major Allergen Alt a 1 in the Allergenicity. 2021, 7 (8), 631.
- Hedayati MT, Arabzadehmoghadam A, Hajheydari Z. Specific IgE against *Alternaria alternata* in atopic dermatitis and asthma patients. *Eur Rev Med Pharmacol Sci*. 2009;13(3):187-91.
- Pose G, Patriarca A, Kyanko V, Pardo A, Fernández Pinto V. Effect of water activity and temperature on growth of *Alternaria alternata* on a synthetic tomato medium. *Int J Food Microbiol*. 2009;135(1):60-63.
- Müller, M., [Alternaria infestation of corn silage and hay]. *Zentralblatt für Mikrobiologie*. 1991;146(7-8):481-8.
- Ren P, Ahearn DG, Crow-Junior SA. Mycotoxins of *Alternaria alternata* produced on ceiling tiles. *J Ind Microbiol Biotechnol*. 1998;20(1):53-54.
- Pedersen NB, MÅRdht PA, Hallberg T, Jonsson N. Cutaneous alternariosis. *Brit J Dermatol*. 1976;94(2):201-209.
- Shugar MA, Montgomery WW, Hyslop-Junior NE. *Alternaria sinusitis*. *Ann Otol Rhinol Laryngol*. 1981;90(3):251-4.
- Brindisi G, Gori A, Anania C, Martinelli I, Capponi M, De Castro G, et al. Subcutaneous Immunotherapy (SCIT) with the New Polymerized Molecular Allergoid Alt a1: A Pilot Study in Children with Allergic Rhinitis Sensitized to *Alternaria Alternata*. *J Clin Med* 2023;12(13):4327.
- Bush RK, Prochnau JJ. *Alternaria*-induced asthma. *J Allergy Clin Immunol* 2004; 113(2):227-34.
- Khan MM. *Allergic Disease*. In *Immunopharmacology*, Springer International Publishing; 2016.
- Ahmed EM, Hussein TA, Barkhas SA. The role of IL-4, IL-10 and specific IgE in a sample of Iraqi food allergic patients. *Plant Archives*. 2021;21:1521-1526.
- Kim HK, Lund S, Baum R, Rosenthal P, Khorram N, Doherty TA. Innate Type 2 Response to *Alternaria* Extract Enhances Ryegrass-Induced Lung Inflammation. *Int Arch Allergy Immunol*. 2014;163(2):92-105.
- Panda SK, Colonna M. Innate Lymphoid Cells in Mucosal Immunity. *Front Immunol*. 2019;10:861.
- Doherty TA, Khorram N, Chang JE, Kim HK, Rosenthal P, Croft M, et al. STAT6 regulates natural helper cell proliferation during lung inflammation initiated by *Alternaria*. *Am J Physiol Lung Cell Mol Physiol* 2012;303(7):L577-88.
- Bartemes KR, Kephart GM, Fox SJ, Kita, H. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. *J Allergy Clin Immunol* 2014;134(3):671-678.
- Doherty TA, Khorram N, Sugimoto K, Sheppard D, Rosenthal P, Cho JY et al.

- Alternaria induces STAT6-dependent acute airway eosinophilia and epithelial FIZZ1 expression that promotes airway fibrosis and epithelial thickness. *J Immunol.* 2012;188(6):2622-9.
22. Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE. RAG-1-deficient mice have no mature B and T lymphocytes. *Cell.* 1992;68(5):869-77.
 23. Verma M, Michalec L, Sripada A, McKay J, Sirohi K, Verma D, et al. The molecular and epigenetic mechanisms of innate lymphoid cell (ILC) memory and its relevance for asthma. *J Exp Med.* 2021; 218(7):e20201354. doi:10.1084/jem.20201354.
 24. Zheng H, Zhang Y, Pan J, Liu N, Qin Y, Qiu L, et al. The Role of Type 2 Innate Lymphoid Cells in Allergic Diseases. *Front Immunol.* 2021;12:586078.
 25. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. *J Immunol.* 2012;188(3):1503-13.
 26. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity.* 2005;23(5):479-90.
 27. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. *Int Immunol.* 2008;20(8):1019-30.
 28. Cayrol C, Duval A, Schmitt P, Roga S, Camus M, Stella A, et al. Environmental allergens induce allergic inflammation through proteolytic maturation of IL-33. *Nat Immunol.* 2018;19(4):375-385.
 29. Smith DE. IL-33 meets allergens at the gate. *Nat Immunol.* 2018;19(4):318-320.
 30. McKenzie ANJ, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity. *Immunity.* 2014;41(3):366-374.
 31. England E, Rees DG, Scott IC, Carmen S, Chan DTY, Chaillan-Huntington, CE, et al. Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signaling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction. *Scientific Reports.* 2023;13(1):9825.
 32. Malling HJ, Agrell B, Croner S, Dreborg S, Foucard T, Kjellman M, et al. Diagnosis and immunotherapy of mould allergy. I. Screening for mould allergy. *Allergy.* 1985;40(2):108-14.
 33. Kuratsuji T. Studies on leukocyte adherence inhibition test. Part II. Clinical applications of LAI test to detect delayed type hypersensitivity in infants and children. *Keio J Med.* 1981;30(2):65-9.
 34. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Evaluating Non-IgE-mediated Allergens' Immunoreactivity in Patients with "Intrinsic" Persistent Rhinitis with Help of the Leukocyte Adherence Inhibition Test. *Eur J Med Health Sci.* 2023;5(1):17-22.
 35. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS, et al. Evaluating Non-IgE-Mediated Allergens' Immunoreactivity in Patients Formerly Classified as "Intrinsic" Asthmatics with Help of the Leukocyte Adherence Inhibition Test. *Eur J Clin Med.* 2023;4(2):1-7.
 36. Olivier CE, Argêntão DGP, Santos RAPG, Silva MD, Lima RPS, Zollner RL. Skin scrape test: an inexpensive and painless skin test for recognition of immediate hypersensitivity in children and adults. *The Open Allergy Journal.* 2013;6:9-17.
 37. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 1976;72:248-54.
 38. Olivier CE, Lima RPS, Pinto DG, Santos RAPG, Silva GKM, Lorena SLS, et al. In search of a tolerance-induction strategy for cow's milk allergies: significant reduction of beta-lactoglobulin allergenicity via transglutaminase/cysteine polymerization. *Clinics.* 2012;67(10):1171-1179.
 39. Olivier CE, Santos RAPG, Lima RPS, Argêntão DGP, Silva GKM, Silva MD. A Novel Utility for an Old Method: The Leukocyte Adherence Inhibition Test Is an Easy Way to Detect the Immunoreactive Interference of the Collection Tube Anticoagulant on Cellular Immunoassays. *Journal of Cell Adhesion.* 2014;Article ID 860427:1-6. Available:<http://dx.doi.org/10.1155/2014/860427>
 40. Olivier CE, Pinto DG, Lima RPS, Silva MD, Santos RAPG, Teixeira APM, et al.

- Assessment of Immunoreactivity against Therapeutic Options Employing the Leukocyte Adherence Inhibition Test as a Tool for Precision Medicine. *Eur J Clin Med.* 2021;2(3):40-45.
41. Olivier CE, Pinto DG, Santos RAPG, Lima RPS. Dextran's interference over the Leukocyte Adherence Inhibition Test. *Academia Letter* 2021, Article (number), 3792.
 42. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Immunoreactivity against Dermatophagoides pteronyssinus Assessed by the Leukocyte Adherence Inhibition Test in Patients with Intrinsic Atopic Dermatitis and Correlated "Intrinsic" Non-IgE-mediated Allergic Conditions. *Eur J Clin Med.* 2021;2(6):45-50.
 43. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Contribution of the Leukocyte Adherence Inhibition Test to the Evaluation of Cellular Immunoreactivity against Latex Extracts for Non-IgE-Mediated Latex-Fruit-Pollen Syndrome in Allergic Candidates to Exclusion Diets and Allergic Desensitization. *Eur J Clin Med.* 2022;3(1):11-17.
 44. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Contribution of the Leukocyte Adherence Inhibition Test for the evaluation of immunoreactivity against gluten extracts in non-IgE-mediated / non-autoimmune Gluten-Related Disorders. *Eur J Clin Med.* 2022;3(2):1-7.
 45. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Leukocyte Adherence Inhibition Test to the assessment of Immunoreactivity Against Cow's Milk Proteins in Non-IgE-Mediated Gastrointestinal Food Allergy. *Eur J Clin Med* 2022, 3 (2), 38-43.
 46. Olivier CE, Pinto DG, Teixeira APM, Santana JLS, Santos RAPGS, Lima RPS. Contribution of the Leukocyte Adherence Inhibition Test to the Diagnosis of Immunoreactivity against Cobalt. *Asian J Immunol.* 2023;6(1):174-184.
 47. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. *Immunity* 2001, 15 (6), 985-95.
 48. Voehringer D, Reese TA, Huang X, Shinkai K, Locksley RM. Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. *J Exp Med.* 2006;203(6):1435-46.
 49. Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. *J Exp Med.* 2006;203(4):1105-16.
 50. Halim TY. Group 2 innate lymphoid cells in disease. *Int Immunol.* 2016;28(1):13-22.
 51. Martinez-Gonzalez I, Mathä L, Steer CA, Ghaedi M, Poon GF, Takei F. Allergen-Experienced Group 2 Innate Lymphoid Cells Acquire Memory-like Properties and Enhance Allergic Lung Inflammation. *Immunity.* 2016;45(1):198-208.
 52. Lloyd CM, Snelgrove RJ. Type 2 immunity: Expanding our view. *Sci Immunol.* 2018; 3(25):eaat1604. DOI: 10.1126/sciimmunol.aat1604.
 53. Anjos J, Fernandes C, Silva BM, Quintas C, Abrunheiro A, Gow NA, Gonçalves T. $\beta(1,3)$ -glucan synthase complex from *Alternaria infectoria*, a rare dematiaceous human pathogen. *Med Mycol.* 2012;50(7): 716-25.
 54. Chruszcz M, Chapman MD, Osinski T, Solberg R, Demas M, Porebski PJ, et al. *Alternaria alternata* allergen Alt a 1: a unique β -barrel protein dimer found exclusively in fungi. *J Allergy Clin Immunol.* 2012;130(1):241-7.e9.
 55. Kumar H, Kawai T, Akira S. Pathogen Recognition by the Innate Immune System. *Int Rev Immunol.* 2011;30(1):16-34.
 56. Mintz-Cole RA, Gibson AM, Bass SA, Budelsky AL, Reponen T, Hershey GK. Dectin-1 and IL-17A suppress murine asthma induced by *Aspergillus versicolor* but not *Cladosporium cladosporioides* due to differences in β -glucan surface exposure. *J Immunol.* 2012;189(7):3609-17.
 57. Kobayashi T, Iijima K, Radhakrishnan S, Mehta V, Vassallo R, Lawrence, et al. Asthma-related environmental fungus, *Alternaria*, activates dendritic cells and produces potent Th2 adjuvant activity. *J Immunol* 2009;182(4):2502-10.
 58. Snelgrove RJ, Gregory LG, Peiró T, Akthar S, Campbell GA, Walker SA, et al. *Alternaria*-derived serine protease activity drives IL-33-mediated asthma exacerbations. *J Allergy Clin Immunol.* 2014;134(3):583-592.e6.

59. Park KH, Lee J, Lee SC, Son YW, Sim DW, Lee JH, et al. Comparison of the ImmunoCAP Assay and AdvanSure™ AlloScreen Advanced Multiplex Specific IgE Detection Assay. *Yonsei Med J.* 2017;58(4):786-792.
60. Sugimoto N, Yamaguchi M, Tanaka Y, Nakase Y, Nagase H, Akiyama H, et al. The basophil activation test identified carminic acid as an allergen inducing anaphylaxis. *J Allergy Clin Immunol In Practice.* 2013;1(2):197-199.
61. Chamani S, Mobasheri L, Rostami Z, Zare I, Naghizadeh A, Mostafavi E. Heavy metals in contact dermatitis: A review. *J Trace Elem Med Biol.* 2023;79:127240.
62. Nordqvist B, Rorsman H. Leucocytic migration in vitro as an indicator of allergy in eczematous contact dermatitis. *Trans St Johns Hosp Dermatol Soc.* 1967;53(2):154-9.
63. George M, Vaughan JH. In vitro cell migration as a model for delayed hypersensitivity. *Proc Soc Exp Biol Med.* 1962;111:514-21.
64. Mirza AM, Perera MG, Maccia CA, Dziubynskij OG, Bernstein IL. Leukocyte Migration Inhibition in Nickel Dermatitis. *Int Arch Allergy Appl Immunol.* 2009;49(6):782-788.
65. Popple A, Williams J, Maxwell G, Gellatly N, Dearman RJ, Kimber I. The lymphocyte transformation test in allergic contact dermatitis: New opportunities. *J Immunotoxicol.* 2016;13(1):84-91.
66. Shirakawa T, Kusaka Y, Fujimura N, Goto S, Morimoto K. The existence of specific antibodies to cobalt in hard metal asthma. *Clin Exp Allergy.* 1988;18(5):451-460.
67. Olivier CE, Lima RPS, Pinto DG, Santos RAPG. The Plasma Preincubation with Papain Before the Assay Suggests that a Gell and Coombs Type II Reaction is been Demonstrated by the Leukocyte Adherence Inhibition Test. *Biomed J Sci Tech Res.* 2021;36(3):28647-28655.
68. Thomson DMP. Assessment of immune status by the leukocyte adherence inhibition test. Academic Press: New York; 1982.
69. Tong AW, Burger DR, Finke P, Barney C, Vandembark AA, Vetto RM. Assessment of the mechanism of the leukocyte adherence inhibition test. *Cancer Res.* 1979;39(2):597-603.
70. Fink A, Heller L, Eliraz A, Weisman Z, Miskin A, Schlezinger M, et al. Allergen-specific leukocyte adherence inhibition (LAI) assay: sensitivity, specificity and mechanism. *Immunol Lett.* 1987;16(1):65-70.
71. Halliday WJ, Maluish A, Miller S. Blocking and unblocking of cell-mediated anti-tumor immunity in mice, as detected by the leukocyte adherence inhibition test. *Cell Immunol.* 1974;10(3):467-475.
72. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. *JAMA,* 2013;310(20):2191-4.

© 2023 Olivier et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/107037>